RU2085210C1 - Agent for treatment of patient with reiter's disease - Google Patents

Abstract

FIELD: medicine, pharmacology. SUBSTANCE: method involves the use of preparation "collalysine" as an agent for treatment of patients with Reiter's disease. EFFECT: enhanced effectiveness of treatment. 1 tbl

Description

 The invention relates to medicine, in particular to medicines, and can be used to treat Reiter's disease.

 To date, the treatment of Reiter's disease presents significant difficulties. However, in recent years there has been an increase in the number of patients with Reiter’s disease, its torpid course and resistance to existing methods of therapy. The latter is due to the complex mechanism of pathological changes in the patient’s body (cross section of disorders of various parts of the immune system, connective tissue metabolism, the protease system and their inhibitors). Known drugs for the treatment of Reiter’s disease, indomethacin and other non-steroidal anti-inflammatory drugs, glucocorticoids [2] However, they are not always effective. In addition, glucocorticosteroid drugs can cause various side effects and complications: stomach expressions with bleeding and perforations, acute psychoses, hypertension, osteoporosis, a manifestation of diabetes mellitus. The use of indomethacin for the treatment of arthritis in Reiter’s disease often leads to an ulcerogenic effect on the gastric mucosa, allergic reactions to urticaria, angioedema, and skin rash.

 The duration of therapy for Reiter’s disease with the use of effective means is very long and even using modern complex methods is 28-35 days.

 The pathogenesis of Reiter's disease is complex and peculiar, different from other rheumatic diseases. Immune and metabolic disorders play a significant role. We found statistically significant (p <0.05) pathological shifts in the immune status (a decrease in serum T-lymphocyte counts that occurred against the background of an increase in the level of B-lymphocytes, A. M. C immunoglobulins and circulating immune complexes), which correlated with impaired connective tissue metabolism (increased levels of glycosaminoglycans in the peripheral blood and their excessive excretion in the urine). It is known that glycosaminoglycans have antigenic properties and are considered as biochemical immunological markers of connective tissue damage.

 The use of the well-known domestic drug collizin (in the form of intramuscular injections of 500 KE) is proposed as a means for treating Reiter's disease.

 The drug is used as follows. Collizine was administered to the patient intramuscularly at 500 KE in 2 ml of isotopic solution of sodium chloride daily, for a course of 15-20 injections.

 Collalizine is known as a therapeutic agent for cicatricial changes in ophthalmic cosmetology practice [1] and is also used in the treatment of organic scleroderma. The ability of collalysin to influence the course of the pathological process in the joints with Reiter’s disease is not known.

 In clinical conditions, we first tested the drug collalizine in 22 patients with Reiter's disease with a duration of the process from 3 months to 2 years. Interphalangeal joints of the feet, ankle and knee joints were most often involved in the process. The lesions were asymmetric, mainly entering in the type of oligo- and polyarthritis, were accompanied by pain and stiffness in the joints involved in the pathological process.

 Collalizine is used in a complex of therapeutic measures after the sanitation of the focus of urogenital infection (doxycycline, sumamed, maxaxquin, local procedures), which plays an important role in the development of the disease (1,2,4) and conjunctivitis therapy (in addition to general antibiotic therapy, 1-3% tetracycline applications were additionally prescribed and 0.5% hydrocortisone ointments). In the control group, 20 patients underwent conventional complex therapy of Reiter's disease.

 As a result of the treatment, a distinct therapeutic effect of collalizine was noted after a short period of time (table).

 When applying traditional therapy to 20 patients with Reiter’s disease, all of the above changes occurred at a later date (table).

 Example 1. Patient K., 19 years old, was admitted to the clinic 02.15.94. Sick 5 months. Diagnosis: Reiter's disease. Sporadic form. Urogenital chlamydia. Polyarthritis. Conjunctivitis. Medium severe course. Assigned to collizine 500 KE intramuscularly daily, for a course of 15 injections. A distinct effect of this drug was noted. Already on the 8th day of therapy, the patient noted the disappearance of stiffness, on the 11th day - pain in the joints, on the 17th day the resolution of inflammatory phenomena around the affected joints was ascertained.

 Example 2. Patient E., 27 years old, was in the clinic with 4.01.94 with a diagnosis of Reiter's disease. Sporadic form. Chronic trichomanosis. Urogenital chlamydia. Oligoarthritis. Keratoconjunctivitis. Severe course. The duration of the disease is 7 months. Received intramuscularly collizin at 500 KU daily, for a course of 20 injections. Subjective sensations in the joints of the lower extremities ceased to bother on day 11, on day 14, a significant decrease in erythema and edema was noted, and on day 21, the absence of local inflammatory phenomena was noted.

 Thus, the use of collalysin for Reiter’s disease significantly reduces the duration of therapy. Side effects are absent.

 Against the background of the treatment with the use of the drug collalysine, as the clinical signs of the rheumatic component of the disease resolved, the parameters of immunity and metabolism of the connective tissue returned to normal.

 In particular, the property of collalysine was significantly established for the first time to significantly reduce the level of glycosaminoglycans. In the control group, the excess concentration of glycosaminoglycans after treatment persisted.

 In the course of collalysin therapy, a distinct immunomodulating effect was observed for the first time, consisting in an increase in the number of T-lymphocytes against a background of a decrease in B-lymphocytes, immunoglobulins A. M, C and circulating immune complexes in peripheral blood. In patients of the control group, in order to normalize the immune status, immunomodulators (tactivin, thymogen) had to be additionally used.

 Thus, the use of the domestic drug collizin in addition to the generally accepted complex therapy of Reiter’s disease can reduce the treatment time.

Claims (1)

 The use of collalizine as a treatment for Reiter's disease.

Images